Vipergen in brief

  • Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies
  • Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies
  • Vipergen introduces the YoctoReactor® (yR) and Binder Trap Enrichment® (BTE) – 2nd generation DEL technologies
  • Vipergen introduces the cellular Binder Trap Enrichment® (cBTE) – 3rd generation DEL screening technology (New – commercial release 2020Q4)
  • The yR, BTE and cBTE technology platforms are exclusively owned by Vipergen and secured by strong patent positions
  • Vipergen is offering different business models, including simple Fee-For-Service.
  • In 2015-22 >75 deals signed, including with top-5 pharma in both USA, EU and Japan
  • The company is privately owned by Gunnar Kjems and Dr. Nils Hansen
  • Board members: Gunnar Kjems (chair) and Dr. Nils Hansen
  • Founded by CEO, Dr. Nils Hansen
  • Founded in 2005
  • Incorporated in Copenhagen, Denmark